Nuvo Research Inc Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mark Bartlett who wrote (6796)	2/25/2001 11:06:41 PM
From: Montana Wildhack	Read Replies (2) of 14101

August 01, 2004 Reuters - Dimethaid Announces Disappointing Sales Nearly two years after entering their arthritis product Pennsaid into the US market, and more than two years in other world markets, Pennsaid has captured only 7% of the now estimated $15B US markets the product is approved in 'While sales continue to expand slowly the overall market growth is keeping us in double digit growth in revenue', said the CEO 'and our 20% average royalty sharing has allowed us to explore other directions'. Analysts had predicted a greater penetration into the COX2 nsaids share now estimated at over $12 billion US annually but retained their current rating on the stock in anticipation of the new product launch next month of "Fungaloid" R. Dimethaid is expected to capture over 50% of the growing onchyomyosis market in its first year now estimated at $3 billion a year in North America. Sales - 210 Expenses - 17.5 NPBT - 140 Net Profit - 114 EPS - 2.28 DMXX closed on the NASDAQ earlier today at 61.25 up 40 cents. ...... Caution. This fictional account may contain forward looking statements wholly based on conjecture and brilliant forecasting of worst case scenarios. All figures in US mallards.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next